A GLP-1 dosage chart is only as good as its sources, so every row here comes from the manufacturer's current US label on DailyMed, read on 2026-09-24, or, for the one unapproved compound, from its published trial. The chart sets the products side by side: how each starts, how it steps up, where it stops, how often it is given and how long it lasts. A second table converts the injected doses into syringe units for powder vials. Nothing here is a plan for anyone; the labels set these doses for their indications, and a prescriber chooses among them.
The all-compounds reference, with research peptides as well, is the peptide dosage chart. Each molecule has its own page: semaglutide, tirzepatide and retatrutide. GLP1Ledger's drug pages cover the products as medicines; this page stays with the figures.
The label chart
| Product (molecule) | Route and schedule | Start | Steps | Maintenance / maximum | Half-life |
|---|---|---|---|---|---|
| Ozempic injection (semaglutide) | SC, once weekly | 0.25 mg × 4 weeks | 0.5 → 1 → 2 mg, ≥4 weeks each | 0.5, 1 or 2 mg; max 2 mg | ~1 week |
| Wegovy injection (semaglutide) | SC, once weekly | 0.25 mg × 4 weeks | 0.5 → 1 → 1.7 mg, 4 weeks each | 2.4 mg (or 1.7 mg); max 7.2 mg | ~1 week |
| Wegovy tablets (semaglutide) | Oral, once daily | 1.5 mg × 30 days | every 30 days | 25 mg | ~1 week |
| Rybelsus (semaglutide) | Oral, once daily | 3 mg × 30 days | 7 mg | 7 or 14 mg | ~1 week |
| Ozempic tablets (semaglutide) | Oral, once daily | 1.5 mg × 30 days | 4 mg | 4 or 9 mg | ~1 week |
| Mounjaro (tirzepatide) | SC, once weekly | 2.5 mg | +2.5 mg, ≥4 weeks each | max 15 mg (10 mg in children 10+) | ~5 days |
| Zepbound (tirzepatide) | SC, once weekly | 2.5 mg × 4 weeks | +2.5 mg, ≥4 weeks each | 5, 10 or 15 mg; max 15 mg | ~5 days |
| Trulicity (dulaglutide) | SC, once weekly | 0.75 mg | 1.5 mg, then +1.5 mg, ≥4 weeks each | max 4.5 mg (1.5 mg in children) | ~5 days |
| Victoza (liraglutide) | SC, once daily | 0.6 mg × 1 week | 1.2 mg | 1.2 or 1.8 mg | 13 hours |
| Saxenda (liraglutide) | SC, once daily | 0.6 mg × 1 week | weekly steps | 3 mg | 13 hours |
| Byetta (exenatide) | SC, twice daily before meals | 5 mcg | 10 mcg after 1 month | 5 or 10 mcg | 2.4 hours |
| Foundayo (orforglipron) | Oral, once daily | 0.8 mg × ≥30 days | 2.5 → 5.5 → 9 → 14.5 mg | max 17.2 mg | 29–49 hours |
| Retatrutide (no label) | SC, once weekly, trial | 2 or 4 mg (some arms) | per trial arm | arms of 1, 4, 8, 12 mg | — |
Sources: the manufacturer labels listed at the foot of this page; the retatrutide row is the phase 2 trial (Jastreboff et al., NEJM 2023, PMID 37366315). "SC" is subcutaneous. The Rybelsus and Ozempic-tablet starting doses are, in the label's words, "not effective for glycemic control": they exist to start treatment. Zepbound's label says its 2.5 mg dose is for treatment initiation and is not approved as a maintenance dosage. Foundayo's molecule, orforglipron, is not a peptide.
What the chart shows that one label does not
The half-life sets the schedule. Read down the last column and the schedules follow: exenatide lasts hours and is injected twice a day, liraglutide about half a day and is injected daily, the three weekly molecules last five to seven days. Semaglutide's label adds that it remains in the circulation for about five weeks after the last dose.
Milligrams mean nothing across products. The same molecule appears at 2.4 mg a week injected and 25 mg a day by mouth on one label: 175 mg a week against 2.4, about 73 times more semaglutide by mass for the same weight-reduction indication. The oral label goes further and states that Rybelsus and Ozempic tablets "are not substitutable on a mg-to-mg basis", although both are semaglutide taken the same way. Between molecules, 2.5 mg of tirzepatide and 0.25 mg of semaglutide are both starting doses. No row converts into another, and the semaglutide to tirzepatide page reports that no label offers a conversion.
Every weekly label escalates slowly. Four weeks per step is the floor on all of them, and the labels give the same reason: to reduce gastrointestinal adverse reactions. Liraglutide steps weekly because it reaches steady state in days.
The injected doses as syringe units
The approved pens and vials are solutions of stated strength and are not measured in units. Powder vials are, and the arithmetic is units = mg ÷ mg/mL × 100 on a U-100 syringe. The concentrations below are common reconstitutions (5 mg/mL is a 10 mg vial with 2 mL; 10 mg/mL a 10 mg vial with 1 mL or a 30 mg vial with 3 mL; 20 mg/mL a 20 mg vial with 1 mL).
| Molecule and dose | 5 mg/mL | 10 mg/mL | 20 mg/mL |
|---|---|---|---|
| Semaglutide 0.25 mg | 5 units | 2.5 units | 1.25 units |
| Semaglutide 0.5 mg | 10 units | 5 units | 2.5 units |
| Semaglutide 1 mg | 20 units | 10 units | 5 units |
| Semaglutide 1.7 mg | 34 units | 17 units | 8.5 units |
| Semaglutide 2.4 mg | 48 units | 24 units | 12 units |
| Tirzepatide 2.5 mg | 50 units | 25 units | 12.5 units |
| Tirzepatide 5 mg | 100 units | 50 units | 25 units |
| Tirzepatide 10 mg | 200 units | 100 units | 50 units |
| Tirzepatide 15 mg | 300 units | 150 units | 75 units |
| Retatrutide 1 mg (trial arm) | 20 units | 10 units | 5 units |
| Retatrutide 4 mg (trial arm) | 80 units | 40 units | 20 units |
| Retatrutide 12 mg (trial arm) | 240 units | 120 units | 60 units |
Any figure over 100 units is more than one 1 mL barrel holds, which is the arithmetic reason tirzepatide and retatrutide are usually worked at 10 to 20 mg/mL and semaglutide at 2.5 to 5 mg/mL. The mg to units page sets out the formula and the tenfold misreadings, the reconstitution pages for semaglutide, tirzepatide and retatrutide work each vial size, and the calculator presets for semaglutide and retatrutide vials do it for any figure entered.
What the chart omits
The labels carry indications, contraindications, a boxed warning on thyroid C-cell tumours on every label here except Byetta's, missed-dose rules and dose adjustments that a chart cannot hold; each row is a summary of section 2 of its label, not a substitute for it. Paediatric doses appear only where they change the maximum. Products no longer marketed in the US (the weekly exenatide pen among them) are not listed because no current label was found for them. Retatrutide's figures are trial arms, not doses anyone has approved. Which dose anyone uses is decided with a prescriber.
Sources and dates
Opened 2026-09-24, manufacturer labels on DailyMed (set id, publication date): Ozempic injection (adec4fd2-6858-4c99-91d4-531f5f2a2d79, 2026-06-10); Wegovy injection and tablets (ee06186f-2aa3-4990-a760-757579d8f77b, 2026-06-30); Rybelsus and Ozempic tablets (27f15fac-7d98-4114-a2ec-92494a91da98, 2026-08-19); Mounjaro (d2d7da5d-ad07-4228-955f-cf7e355c8cc0, 2026-09-02); Zepbound (487cd7e7-434c-4925-99fa-aa80b1cc776b, 2026-09-02); Trulicity (463050bd-2b1c-40f5-b3c3-0a04bb433309, 2026-08-10); Victoza (5a9ef4ea-c76a-4d34-a604-27c5b505f5a4, 2025-11-17); Saxenda (3946d389-0926-4f77-a708-0acb8153b143, 2026-06-15); Byetta (53d03c03-ebf7-418d-88a8-533eabd2ee4f, 2025-09-08); Foundayo (8ac446c5-feba-474f-a103-23facb9b5c62, 2026-08-13) — sections 2 and 12.3 of each. Jastreboff AM et al., N Engl J Med 2023;389:514-526 (PMID 37366315), abstract. Unit and mass arithmetic by this site. Corrections go to the contact page.